LogicBio Therapeutics Inc banner
L

LogicBio Therapeutics Inc
F:0IF

Watchlist Manager
LogicBio Therapeutics Inc
F:0IF
Watchlist
Price: 2.04 EUR
Market Cap: €67.2m

During the last 3 months LogicBio Therapeutics Inc insiders bought 67.7m EUR , and have not sold any shares.

The last transaction was made on Mar 5, 2026 by Busch Richard , who bought 78.2k EUR worth of 0IF shares.

Last Transactions:
Busch Richard
€+78.2k
Busch Richard
€+103.5k
Busch Richard
€+230.4k
Mateen Justin
€+1.9m
Genoot Asher
€+32.5m
Ho Michael
€+32.5m
Busch Richard
€+200k
Busch Richard
€+290.5k
View All Transactions

During the last 3 months LogicBio Therapeutics Inc insiders bought 67.7m EUR , and have not sold any shares.

The last transaction was made on Mar 5, 2026 by Busch Richard , who bought 78.2k EUR worth of 0IF shares.

Sold
0-3
months
0 EUR
0
3-6
months
0 EUR
0
6-9
months
0 EUR
0
9-12
months
0 EUR
0
Bought
0-3
months
4
67.4m EUR
3-6
months
1
290.5k EUR
6-9
months
No Insider Transactions
0
0 EUR
9-12
months
No Insider Transactions
0
0 EUR

LogicBio Therapeutics Inc
Insider Trading Chart

LogicBio Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

LogicBio Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

LogicBio Therapeutics Inc
Glance View

Market Cap
67.2m EUR
Industry
Biotechnology

LogicBio Therapeutics, Inc. engages in the development of genome editing technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2018-10-19. The company is focused on genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. Its genome editing platform, GeneRide, is an approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid repair process, potentially to durable therapeutic protein expression levels. Its gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate, LB-001 is developed for the treatment of methylmalonic acidemia (MMA) in pediatric patients. LB-001 is designed to introduce a functional copy of the methylmalonyl-CoA mutase (MUT) gene into the genome of MMA patients. The company is developing LB-401 for the treatment of hereditary tyrosinemia type 1. The company is also developing LB-301 for the treatment of Crigler-Najjar syndrome (CN).

0IF Intrinsic Value
11.11 EUR
Undervaluation 82%
Intrinsic Value
Price
L

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett